Trial Profile
An Ascending Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Gimsilumab in Healthy Subjects and Subjects With Ankylosing Spondylitis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Gimsilumab (Primary)
- Indications Ankylosing spondylitis
- Focus Adverse reactions
- Sponsors Kinevant Sciences GmbH
- 21 Apr 2021 Results (n=36) assessing safety and pharmacokinetics of subcutaneous gimsilumab in healthy subjects, presented at the 122nd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics and International Transporter Consortium Workshop 4
- 09 Apr 2020 Status changed from active, no longer recruiting to completed.
- 19 Mar 2020 Status changed from recruiting to active, no longer recruiting.